FDA ends summer with fresh batch of breakthrough device designations

FDA has closed out the summer with another batch of breakthrough device designations, including awards of regulatory privileges to products used in the treatment and detection of cancers. The designation gives sponsors potentially speedier review from regulators for products for hard-to-treat conditions or those with few options.